Análisis de 23 pacientes con infección por VIH y Covid-19. Estudio descriptivo / Analysis of 23 patients with HIV infection and Covid-19. Descriptive study

Las características clínicas, el diagnóstico, el pronóstico, el tratamiento y la profilaxis de la infección por el coronavirus SARS-CoV-2 en los pacientes infectados por el VIH, son muy similares a los de la población general cuando estos se encuentran con supresión de la replicación viral con el tratamiento antirretroviral y tienen una cifra de linfocitos T CD4 + > de 200 células/uL. El tiempo medio de incubación es de 5 días (entre 2 y 14 días). En sujetos VIH positivos, cuánto mayor es la carga viral plasmática para VIH y el recuento de CD4 + es < 200 cél/uL, el tiempo que transcurre entre la infección por el coronavirus y la aparición de las manifestaciones clínicas es menor. En la población general, el 70-80% de individuos tienen una infección por SARS-CoV-2 leve/moderada, un 20-25% grave y un 5% muy grave que requiere internación en UTI. En los pacientes infectados por el VIH se desconoce esta proporción, aunque estudios preliminares consideran que las proporciones serían del 66%, 22% y 12%, respectivamente25. Se presenta una serie de 23 pacientes con coinfección SARS-CoV-2/VIH y se analizan las características epidemiológicas, clínicas y la evolución en relación con ambas infecciones

The clinical characteristics, diagnosis methods, medical prognosis, treatment alternatives and prophylaxis of coronavirus SARS-CoV-2 infection in HIV infected individuals are very similar in patients under HAART with undetectable viral load and CD4+ > than 200 cell/uL. The mean incubation time is of 5 days (range 2 to 14 days). In HIV-seropositive patients, with high viral load and CD4 < 200 cell/ uL, the time between infection for coronavirus and the onset of symptoms is minor. In the general population, 70% to 80% of individuals infected by SARS-CoV-2 develops a mild to moderate disease; 20% to 25% severe forms and 5% develops very severe clinical compromise that requieres intensive therapy unit income. In HIV-positive patients these percentages would be 66%, 22% y 12%, respectively25. Here we present a series of 23 HIV-seropositive patients coinfected by coronavirus SARS-CoV-2; we analyzed the epidemiology, clinical manifestations and the evolution related with both infections

Long-term non-progressor (ltnp) hiv infection. a case report of an 81-year-old woman / Infecção por hiv de longo prazo não progressor (ltnp). relato de caso de uma mulher de 81 anos / Infección por vih no progresiva a largo plazo (ltnp). reporte de caso de una mujer de 81 años

An 81-year-old woman, long-term non-progressor HIV infected, asymptomatic, not using ART, with a seven-year clinical follow-up in a reference unit, TCD4+ cell count values ranged from 719 to 1151 cells/µl, TCD8+ from 579 to 897 cells/µl and a viral load with higher value of 51 viral copies/ml but with undetectable results in most of the tests performed. The report of the long-term non-progressor HIV carrier aged over 80 years is somewhat unusual, considering the physiological/immunological changes that occur with the aging process concomitantly with HIV infection.

Mulher de 81 anos, infectada pelo HIV há muito tempo, não progressor, assintomática, sem uso de TARV, com acompanhamento clínico de sete anos em unidade de referência, os valores de contagem de células TCD4+ variaram de 719 a 1151 células/ µl, TCD8+ de 579 a 897 células/µl e uma carga viral com maior valor de 51 cópias virais/ml, mas com resultados indetectáveis na maioria dos testes realizados. O relato do portador de HIV de longa data não progressor com idade superior a 80 anos é um tanto incomum, considerando as alterações fisiológicas/imunológicas que ocorrem com o processo de envelhecimento concomitante à infecção pelo HIV.

Mujer de 81 años, infectada por VIH no progresor de larga evolución, asintomática, no usuaria de TAR, con seguimiento clínico de siete años en una unidad de referencia, los valores de recuento de células TCD4+ oscilaron entre 719 y 1151 células/ µl, TCD8+ de 579 a 897 células/µl y una carga viral con mayor valor de 51 copias virales/ml pero con resultados indetectables en la mayoría de las pruebas realizadas. El reporte de portadores de VIH no progresores a largo plazo mayores de 80 años es algo inusual, considerando los cambios fisiológicos/inmunitarios que ocurren con el proceso de envejecimiento concomitante con la infección por VIH.

Respuesta inmune contra SARS-CoV-2 en personas con VIH convalecientes de COVID-19 / SARS-CoV-2 immunity in PWH

Desde principios de la pandemia de SARS-CoV-2 se ha debatido el curso de la enfermedad COVID-19 en personas con VIH. Por un lado, la inmunodeficiencia derivada de la infección por VIH y la mayor prevalencia de comorbilidades estarían asociadas al desarrollo de enfermedad grave. Por otro lado, la disfunción inmunológica podría evitar una respuesta inflamatoria exacerbada. En este trabajo de revisión analizamos la evidencia disponible en cuanto a la relación entre la manifestación clínica de COVID-19 y la respuesta inmune humoral y celular contra SARS-CoV-2 en el contexto de la coinfección con VIH. La bibliografía sugiere que las personas con VIH que reciben tratamiento antirretroviral logran respuestas eficaces contra SARS-CoV-2, a pesar de presentar algunas de las funciones celulares alteradas. Esto sugiere un impacto significativo de la terapia antirretroviral, no solo en el control del VIH sino en potenciar la inmunidad para restringir otras infecciones.

Since the beginning of SARS-CoV-2 pandemic, the course of COVID-19 in people with HIV has been debated. On the one hand, the immunodeficiency derived from HIV infec-tion and the higher prevalence of comorbidities would be associated with severe disease. On the other hand, due to its immunological dysfunction, an exacerbated inflam-matory response might be avoided.In this review, we analyzed the evidence regarding the clinical manifestation of COVID-19 and the humoral and cellular immune response against SARS-CoV-2 during HIV coinfection. The literature suggests that people with HIV on antiretroviral treatment achieved effective responses against SARS-CoV-2, despite having altered cell func-tions. This indicates a remarkable impact of antiretroviral therapy, not only in controlling HIV but also in boosting immunity to restrict other infections

Sarcoma de Kaposi tipo linfangiomatoso: comunicación de un caso / 9 LYMPHANGIOMATOUS KAPOSI'S SARCOMA: CASE REPORT

El sarcoma de Kaposi linfangiomatoso es una variante clínica rara del sarcoma de Kaposi. Tiene la característica de presentarse como cavidades con contenido líquido que muchas veces se confunden con enfermedades ampollares de la piel. Presentamos un paciente masculino con antecedente de infección por VIH asociado a sarcoma de Kaposi clásico, diseminado a nivel pulmonar, gastrointestinal y cutáneo. Tras dos ciclos de quimioterapia mejoró el compromiso sistémico, pero comenzó con ampollas en ambos muslos, por lo que junto con estudios clínicos y estudios complementarios se llegó al diagnóstico de sarcoma de Kaposi linfangiomatoso.

Lymphangiomatous Kaposi's sarcoma is a rare clinical variant of Kaposi's sarcoma. It has the characteristic of appearing as cavities with liquid content that are often confused with blistering skin diseases. We present a male patient with a history of HIV infection associated with classic Kaposi's sarcoma, disseminated to the pulmonary, gastrointestinal and skin levels. After two cycles of chemotherapy, the systemic involvement improved but she began with blisters on both thighs, from which, together with clinical studies and complementary studies, a diagnosis of lymphangiomatous Kaposi's sarcoma was reached.

Non/hypo-response to hepatitis B vaccination and influencing factors in HIV-infected patients in the context of different immunization schedules / 中华流行病学杂志

Objective: To study the non/hypo-response to hepatitis B vaccination in HIV-infected patients, identify the influencing factors and provide evidence for the development of hepatitis B prevention and control strategies and measures for special population. Methods: On the basis of the randomized controlled trial of 20 µg hepatitis B vaccine immunization at 0-1-6 month, 0-1-2-6 month and 60 µg hepatitis B vaccine immunization at 0-1-2-6 month, the HIV-infected patients who completed one-month follow-up after the full course vaccination were selected as study subjects. Quantification of antibody to hepatitis B surface antigen (anti-HBs) in serum samples was performed by using chemiluminescent microparticle immunoassay (CMIA) and demographic characteristics, disease history, HIV infection and treatment status of the study subjects were collected. Statistical analysis was conducted by χ2 test, t test, unconditional logistic regression and interaction analyses. Results: The non/hypo-response rates to hepatitis B vaccination were 34.65% (35/101), 24.49% (24/98) and 10.99% (10/91) in 20 µg group at 0-1-6 month or 0-1-2-6 month and 60 µg group at 0-1-2-6 month (P<0.001), respectively. Logistic regression analysis showed that after controlling for confounding factors, the risk for non/hypo-response was 0.22 times higher in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in patients receiving 20 µg hepatitis B vaccine at 0-1-6 month (95%CI: 0.10-0.50), the risk for non/hypo-response was higher in men than in women (OR=3.65, 95%CI: 1.88-7.07), and the risk for non/hypo-response was 2.64 times higher in those without hepatitis B vaccination history than in those with hepatitis B vaccination history (95%CI: 1.10-6.32). Moreover, there were multiplicative interactions between immunization schedule and gender (OR=2.49, 95%CI: 1.24-5.00). Conclusion: The non/hypo-response rate to hepatitis B vaccination was significantly lower in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in those receiving 20 µg hepatitis B vaccine at 0-1-6 month and 0-1-2-6 month. Gender, vaccination schedule and history of hepatitis B vaccination were the influencing factors of the non/hypo-response to hepatitis B vaccination. There was a multiplicative interaction between vaccination schedule and gender, and men receiving 20 µg hepatitis B vaccines had a higher risk for non/hypo-response to hepatitis B vaccination.

VIH y SARS-CoV-2: aspectos a considerar para enfrentar esta nueva pandemia / HIV and SARS-CoV-2: points to consider to face this new pandemic

En diciembre de 2019 una nueva especie de ß-coronavirus causante de neumonía fue identificada en la ciudad China de Wuhan, el cual posteriormente fue denominado SARS-CoV-2. Este virus de ácido ribonucleico presenta ciertas similitudes con otros virus del mismo material genético, dentro de ellos se ha visto que la infección por virus de la inmunodeficiencia humana se asemeja en diversos aspectos a la infección por SARS-CoV-2. En este comentario presentamos algunas de las similitudes virológicas, inmunológicas, clínicas y farmacológicas entre estos dos virus, las cuales podrían permitirnos entender de mejor manera la inmunopatogenia de COVID-19, así como también tomar algunas decisiones en cuanto al manejo antiviral.

In December 2019, a new species of pneumonia-causing betacoronavirus was identified in Wuhan, China, which was later identified as SARS-CoV-2. This RNA virus presents certain similarities with other viruses of the same genetic material. It has been seen that infection by human immunodeficiency virus resembles the infection by SARS-CoV-2 in various aspects. In this comment, we present some of the virological, immunological, clinical, and pharmacological similarities between HIV and SARS-CoV-2, which could allow us to understand the immunopathogenesis of COVID-19 better, as well as make some decisions in regarding antiviral management.

Lípidos anormales e inmunidad adquirida Síndrome de Deficiencia: Asociación de Suero Lípidos con estatus de VIH / Abnormal Lipids and Acquired Immune Deficiency Syndrome: Association of Serum Lipids with HIV Status

Context and Aim: Hematological abnormalities are amongst the most common complications of infection with HIV.There have been quite a few studies on the alterations in lipid profile, too, though the results have largely been inconclusive. The present study was carried-out to assess CD4 cell counts and lipid profile in the HIV infected and AIDS patients in the Indian population and correlates them with the sero-negative controls. Materials and Methods: The present study was designed as a cross-sectional, hospital-based study to assess CD4 cell counts and lipid profile in the HIV infected and AIDS patients in the Indian population and correlates them with the sero-negative controls. Evaluation of lipid profile was done using Erba EM 360, an automated analyzer powered by a diffraction grating photometer while CD4 cell counts were evaluated using Partec Cyflow Counter. Statistical analysis used: The data was analyzed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Comparison of the said parameters was done using Analysis of Variance (ANOVA) and posthoc Games-Howell test. p-value of <0.05 was considered statistically significant. Results: The levels of total cholesterol and low-density lipoproteins (LDLs) were significantly decreased while triglycerides and very low density lipoproteins (VLDLs) were significantly increased in the HIV infected and AIDS patients when compared with the sero-negative controls. Conclusion: Total cholesterol, LDLs, triglycerides and VLDLs were significantly altered in the HIV infected and AIDS patients when compared with the sero-negative controls.

Epidemiological profile of HIV older adults who are patients in a reference center in Aracaju-SE / Perfil epidemiológico dos pacientes idosos com HIV em um centro de referência de Aracaju-SE / Perfil epidemiológico de pacientes ancianos con VIH en un centro de referencia en Aracaju-SE

Background and objectives: Acquired Immunodeficiency Syndrome (AIDS) is a disease caused by HIV. 3% of the people living with HIV/AIDS in Brazil are 60 years old or over. Although older adults correspond to a small percentage, there has been a significant increase in the incidence in this group in recent years. Thus, HIV infection in older adults is a reality, however, literature hardly addresses this topic. The objective is to study the epidemiological clinical profile of older adults living with HIV monitored at a referral center. Methods:This is an observational, descriptive, cross-sectional study with data collection obtained from the medical records of the STI/AIDS outpatient clinic at a reference center. The data were sociodemographic, clinical and laboratory, collected from September 2018 to February 2019. Results:In the reference center, 309 older adults were registered, representing 6.7% of all patients registered in the service. Of these, 75.6% are men, 38% are married, 70% heterosexual and approximately 50% with low education. Comorbidities are associated, with dyslipidemia (54%) being the main one. At the time of diagnosis, 65.8% had detectable viral load and 62% had CD4 + cells <500 cls/mm³ and after therapeutic follow-up, only 20% had detectable viral load. Several therapeutic regimens are used, the main one being Tenofovir, Lamivudine and Efavirenz (35.3%). Conclusion: The epidemiological profile of the population served in the region follows national and global characteristics, with a predominance of men, heterosexuals, married and with low education.(AU)

Justificativa e Objetivos: A Síndrome da Imunodeficiência Adquirida (SIDA) é uma doença causada pelo HIV. Das pessoas vivendo com HIV(PVHIV)no Brasil, 3% apresentam 60 anos ou mais. Apesar dos idosos corresponderem a um pequeno percentual, há aumento significativo da incidência nesse grupo nos últimos anos. Dessa forma, a infecção pelo HIV em idosos é uma realidade, contudo, a literatura pouco aborda esse tema. O objetivo do trabalho é estudar o perfil clínico epidemiológico dos idosos vivendo com HIV acompanhados em um centro de referência. Métodos: Trata-se de um estudo observacional, descritivo, de corte transversal, com coleta de dados obtida através dos prontuários do ambulatório de IST/SIDA de um centro de referência. Os dados sociodemográficos, clínicos e laboratoriais, foram coletados no período setembro de 2018 a fevereiro de 2019. Resultados: No centro de referência, estão cadastrados 309 idosos, representando 6,7% de todos os pacientes matriculados no serviço. Destes, 75,6% são homens, 38% casados, 70% de orientação heterossexual e aproximadamente 50% com baixa escolaridade. Comorbidades estão associadas, sendo a dislipidemia (54%) a principal. No momento do diagnóstico, 65,8% apresentavam carga viral (CV) detectável,62% tinham células CD4+ < 500céls/mm³ e após seguimento terapêutico apenas 20% apresentavam CV detectável. Vários esquemas terapêuticos foram utilizados, sendo o principal Tenofovir, Lamivudina e Efavirenz (35,3%). Conclusão: O perfil epidemiológico da população atendida na região segue as características nacionais e mundiais, com predomínio de homens, heterossexuais, casados e de baixa escolaridade.(AU)

Justificación y Objetivos: El Síndrome de Inmunodeficiencia Adquirido(SIDA) es una enfermedad causada por el VIH. De las personas que viven con el VIH (PVVIH) en Brasil, el 3% tiene 60 años o más. Aunque los adultos mayor es corresponden a un pequeño porcentaje, en los últimos años se ha producido un aumento significativo de la incidencia en este grupo. La infección por VIH en los adultos mayores es una realidad; sin embargo, la literatura aborda poco este tema. El objetivo de este trabajo es estudiar el perfil clínico epidemiológico de adultos mayores que conviven con el VIH y se atienden en un centro de referencia. Métodos: Se trata de un estudio observacional, descriptivo, de corte transversal, con datos obtenidos de los registros de ETS/SIDA de un centro de referencia. Se recogieron datos sociodemográficos, clínicos y de laboratorio desde septiembre de 2018 hasta febrero de 2019. Resultados: En el centro de referencia están registrados309 adultos mayores, que representan el 6,7% de todos los pacientes inscriptos en el servicio. De ellos, el 75,6% es del sexo masculino, el 38%, casado, el 70% con orientación heterosexual y aproximadamente el 50% con baja escolaridad. De las comorbilidades asociadas, la dislipidemia esla principal (54%). En el momento del diagnóstico, el 65,8% tenía una carga viral detectable (CV), el 62%tenía células CD4+<500 células/mm³ y después del seguimiento terapéutico sólo el 20% tenía CV detectable. Se utilizaron varios esquemas terapéuticos, siendo los principales el Tenofovir, la Lamivudina y el Efavirenz (35,3%). Conclusión: El perfil epidemiológico de la población atendida en la región sigue las características nacionales e internacionales, con predominio de hombres heterosexuales, casados y de baja escolaridad.(AU)

Sifilides elegantes de BROCQ en una paciente con SIDA y sífilis secundaria. Presentación de un caso y revisión de la literatura / 5 BROCQ ELEGANTS SYPHILIDES IN A PATIENT WITH AIDS AND SECONDARY SYPHILLIS

La coinfección entre el Treponema pallidum y el virus de la inmunodeiciencia humana (VIH) altera el curso clínico clásico de la sífilis aumentando la probabilidad de aparición de formas atípicas del secundarismo sifilítico. Entre estas formas se ha descripto a la sífilis elegante, entidad caracterizada por un exantema maculopapuloso descamativo, de aspecto anular, por lo general, con indemnidad de las regiones palmo plantar y de las mucosas. Se presenta un caso de sífilis secundaria, con lesiones típicas por su aspecto y localización, de sifílides elegantes en una paciente con diagnóstico de sida

Co-infection between Treponema pallidum and HIV alters the classic clinical course of syphilis, increasing the likelihood of atypical forms of syphilitic secondaryism. Among these forms, elegant syphilis has been described, an entity characterized by a desquamating maculopapular rash of annular appearance, with indemnity of the palmoplantar surface and mucous regions. Here, we present a case of secondary syphilis with typical lesions of elegant syphillides, in a patient diagnosed with AIDS

Terapêuticas que reduzem a transmissão vertical do HIV / Therapeutics that reduce vertical HIV transmission

O vírus da imunodeficiência humana (HIV) é um retrovírus com genoma ácido ribonucleico da família Retroviridae (retrovírus) e subfamília Lentivirinae, que necessita, para multiplicar-se, de uma enzima denominada transcriptase reversa, responsável pela transcrição do ácido ribonucleico viral para uma cópia de ácido desoxirribonucleico. A transmissão ocorre por via predo- minantemente sexual, mas também pelo contato com sangue contaminado, pela via transplacentária ou por aleitamento materno. A transmissão vertical é a principal via de infecção pelo HIV em crianças. É estimado que 15% a 30% da população infan til nascida de mães soropositivas para o vírus da imunodefici- ência humana adquirem o vírus com maior frequência durante o trabalho de parto, pós-parto ou por meio da amamentação. Tem-se utilizado para gestantes a terapia antirretroviral combi- nada, a qual reduziu 20 vezes nas taxas de transmissão vertical. O objetivo deste trabalho é discutir sobre as drogas que retar- dam a progressão da imunodeficiência, aumentando o tempo e a qualidade de vida do portador do vírus da imunodeficiência humana, além de especificar a terapia que obteve mais sucesso. O início de terapia antirretroviral combinada em uma fase precoce da gestação em pacientes infectadas tem o potencial de melhorar substancialmente a saúde materna e a sobrevida, além de tornar a transmissão vertical um evento raro.

The Human Immunodeficiency Virus (HIV) is a retrovirus with a ribonucleic acid (RNA) genome of the Retrovirus Family and subfamily Lentivirinae, which needs an enzyme called reverse transcriptase to be multiplied, which is responsible for trans- cribing viral ribonucleic acid to a deoxyribonucleic acid (DNA) strand. Transmission occurs predominantly sexually, but also through contact with blood, transplacental, or through breastfee- ding. Vertical transmission is the main route of HIV infection in children. It is estimated that 15 to 30% of the child population born to HIV-positive mothers acquire the virus most often du- ring labor, postpartum, or through breastfeeding. Highly Active Antiretroviral Therapy has been used for pregnant women, with 20-fold reduction of vertical transmission rates. The aim of this paper is to discuss about the drugs that slow the progression of immunodeficiency, increasing the time and quality of life of pa- tients with Human Immunodeficiency Virus, and specifying the most successful therapy. Initiation of Highly Active Antiretro- viral Therapy at an early stage of pregnancy in infected patients has the potential to improve maternal health and survival subs- tantially, and makes vertical transmission a rare event.

Neurochagas: atualização clínica / Neurochagas: clinical update

A doença de Chagas ainda é uma doença tropical muito prevalente no Brasil. Pode apresentar duas fases (aguda e crônica) e exibe grandes repercussões, sobretudo as que envolvem o sistema nervoso periférico e/ou central. Com o aumento do número de pessoas vivendo em estado (transitório ou permanente) de imunossupressão, os casos de manifestações neurológicas por neurochagas aumentaram, e este tornou-se um importante diagnóstico diferencial com outras doenças oportunistas. Este artigo teve como objetivo revisar os principais aspectos clínicos e terapêuticos da doença de Chagas no sistema nervoso central.

Chagas disease is still a very prevalent tropical disease in Brazil. It can have two phases - acute and chronic ­ and shows major repercussions, especially those involving the peripheral and/ or central nervous system. With the increase in the number of people living in the (transient or permanent) state of immunosuppression the cases of neurological manifestations of Chagas disease increased and this became an important differential diagnosis with other opportunistic diseases. This article aimed to review the main clinical and therapeutic aspects of central nervous system Chagas disease

Inflamación sistémica y desregulación inmune: rol en la patogénesis de la coinfección VIH/VHC / Systemic inflammation and immune dysregulation: role in the pathogenesis of HIV / HCV coinfection

La disfunción inmune asociada a la infección por el virus de la inmunodeficiencia humana (VIH) es generada por una estimulación crónica del sistema inmune secundaria a la imposibilidad del organismo de erradicar el virus. La misma se encuentra exacerbada en el contexto de la coinfección por el virus de la hepatitis C (VHC). La inflamación sistémica producto de la coinfección por ambos virus genera un aumento de la morbilidad y mortalidad en los individuos afectados. Son varios los mediadores solubles de activación inmunológica, como IP-10, TNF-α, IL-6, IL-1ß (marcadores de inflamación sistémica); IL-17 (linfocitos T CD4+ Th17); IL-2, IFN-γ (linfocitos T CD4+ Th1); IL-8 (inducción de neutrofilia); CD23s, ICAMs, CD14s, CD163s (marcadores de activación de monocitos/macrófagos), niveles circulantes de lipopolisacárido (LPS) (translocación bacteriana); entre otros. Actualmente se necesitan más estudios para lograr definir cuáles serían los biomarcadores de progresión óptimos para el seguimiento de los individuos coinfectados por VIH/VHC. El objetivo de esta revisión es realizar una reseña sobre los mecanismos inmunopatológicos de la infección por VIH/VHC involucrados en la inflamación, daño hepático y su impacto en la morbimortalidad de los individuos coinfectados

The immune dysfunction associated with Human Immunodeficiency Virus (HIV) infection is generated by a chronic stimulation of the immune system, because of the inability to eradicate the virus from the host. This immune dysfunction is exacerbated in the context of coinfection with Hepatitis C Virus (HCV). Systemic inflammation caused by coinfection with both viruses generates an increase in morbidity and mortality in affected individuals. There are several soluble mediators of immunological activation, such as IP-10, TNF-α, IL-6, IL-1ß (systemic inflammation markers); IL-17 (CD4+ T cells Th17); IL-2, IFN-γ (CD4+ T cells Th1); IL-8 (neutrophilia); CD23s, ICAMs, CD14s, CD163s, lipopolysaccharide (LPS) (monocyte/macrophage activation markers and bacterial translocation); among others. Currently, more studies are needed to define optimal progression biomarkers for the follow-up of HIV/HCV coinfected individuals. In this review, we focus on the immunopathological mechanisms of HIV/HCV infection involved in inflammation, liver damage and its impact on the morbidity and mortality of affected individuals

Neurocysticercosis and HIV Infection: what can we learn from the published literature? / Neurocisticercosis e infección por VIH: ¿Qué se puede aprender de la literatura reportada?

ABSTRACT Infections caused by the human immunodeficiency virus (HIV) and by the larvae of Taenia solium (i.e., cysticercosis) are still widespread in many developing countries. Both pathologies modify host immune status and it is possible that HIV infection may modulate the frequency and pathogeny of cysticercosis of the central nervous system (i.e., neurocysticercosis [NCC]). Objective: To describe published cases of NCC among HIV-positive patients and to evaluate whether the characteristics of NCC, including frequency, symptoms, radiological appearance, and response to treatment differed between HIV-positive and HIV-negative patients. Methods: Forty cases of NCC/HIV co-infected patients were identified in the literature. Clinical and radiological characteristics, as well as response to treatment, were compared with non-matching historical series of NCC patients without HIV infection. Results: Most of these patients had seizures and multiple vesicular parasites located in parenchyma. Clinical and radiological characteristics were similar between HIV-positive and HIV-negative patients with NCC, as well as between immunocompromised and non-immunocompromised HIV-positive patients. Conclusion: Our review did not reveal clear interactions between HIV and NCC. This may be partially due to the small number of cases and reliance on published research. A systematic, multi-institutional effort aiming to report all the cases of this dual pathology is needed to confirm this finding and to clarify the possible relationship between both pathogens.

RESUMO Las infecciones causadas por el virus de inmunodeficiencia humana (VIH) y la larva de la Tenia solium siguen estando diseminadas en países en vías de desarrollo. Ambas patologías modifican el estado inmune y es posible que la infección por el VIH module la frecuencia y la patología de la neurocisticercosis (NCC). Objetivo: Describir los casos publicados de NCC en los pacientes VIH positivos y evaluar si las características de la NCC, incluyendo frecuencia, síntomas, presentación radiológica, respuesta a tratamiento, difieren entre los sujetos VIH positivos y VIH negativos. Métodos: Cuarenta casos con coinfección NCC/VIH fueron identificados en la literatura. Se compararon sus características clínico-radiológicas, así como su respuesta al tratamiento con diferentes series de casos históricos no pareados. Resultados: La mayoría de los pacientes NCC/VIH tenían epilepsia y múltiples parásitos vesiculares en el parénquima. Las características clínico-radiológicas de la NCC así como la evolución de los pacientes fueron similares entre pacientes VIH positivos y negativos, así como entre pacientes VIH inmunocomprometidos y no inmunocomprometidos. Conclusión: No encontramos interacciones claras entre VIH y NCC. Este resultado puede haber sido influenciado por el pequeño número de casos y la parcialidad de la información publicada. Un esfuerzo multiinstitucional, sistemático encaminado a reportar todos los casos de esta patología dual es necesario para confirmar estos resultados y esclarecer la relación entre patógenos.

Antiretroviral therapy immunologic non-response in a Brazilian population: association study using pharmaco- and immunogenetic markers

ABSTRACT Background: Antiretroviral therapy (ART) saved millions from HIV-1 infection and AIDS, but some patients do not experience adequate CD4+ T cells gain despite achieving viral suppression. The genetic component of this condition is not yet completely elucidated. Objective: To identify predictive genetic markers of immune response to ART. Methods: Case-control study. Out of 176 HIV-infected patients recruited in the city of Recife, Northeast Brazil, 67 patients with no immunologic response were the cases and the remaining 109 patients who responded were the controls. A set of 94 selected single nucleotide polymorphisms (SNPs) involved in antiretroviral drugs pharmacodynamic pathways and immune system homeostasis were genotyped, while the remaining 48 were ancestry informative markers (AIMs) for controlling for eventual hidden population structure. Results: Male patients were overrepresented in non-responder group (p = 0.01). Non-responders also started with lower absolute CD4+ T cell counts (p < 0.001). We found five SNPs significantly associated with the outcome, being three more frequent in non-responders than responders: rs2243250 (IL4) A allele (p = 0.04), rs1128503 (ABCB1) A allele (p = 0.03) and rs707265 (CYP2B6) A allele (p = 0.02), whereas the other two were less frequent in non-responders: rs2069762 (IL2) C allele (p = 0.004) and rs4646437 (CYP3A4) A allele (p = 0.04). Conclusion: Some significant univariate associations remained independently associated at multivariate survival analysis modeling, such as pre-treatment CD4+ T cells counts, IL2 and ABCB1 genotypes, and use of protease inhibitors, yielding a predictive model for the probability for immune response. More studies are needed to unravel the genetic basis of ART immunological non-response.

Interleukin-6 and Interferon-α Levels in Gingival Crevicular Fluid in HIV-1 Patients with Chronic Periodontitis / Niveles de Interleukin-6 e Interferon-α de Fluido Crevicular Gingival en Pacientes VIH-1 con Periodontitis Crónica

ABSTRACT: The influence of cytokine on the progression of chronic periodontitis in human immunodeficiency virus (HIV) patients is still controversial and poorly investigated. This study aimed to analyze and compare IL-6 and IFN-α levels in the gingival crevicular fluid of HIV-1-positive and HIV-1-negative patients with chronic periodontitis and different grades of tissue destruction and inflammation. Samples from the gingival crevicular sulcus were obtained from 35 HIV-1-positive individuals with chronic periodontitis and 35 seronegative patients with chronic periodontitis. Probing depth and clinical attachment level, as well as the results of the Enzyme-Linked Immunosorbent Assay for confirmation of patient diagnostics, were evaluated. Statistical analyses were performed using Student t, Mann-Whitney and Spearman tests. IL-6 levels were significantly lower, while IFN-α levels were significantly higher in HIV-1 patients. Clinical attachment level was directly associated with IFN-α levels in HIV-1 carriers, connected to probing depth in these patients. Clinical data in association with gingival crevicular fluid cytokine levels may reveal a localized immunological response pattern, which may contribute to the understanding of periodontitis pathogenesis in HIV-1 carriers.

RESUMEN: La influencia de la citocina en la progresión de la periodontitis crónica en pacientes con el virus de la inmunodeficiencia humana (VIH) sigue siendo controvertida y poco investigada. Este estudio tuvo como objetivo analizar y comparar los niveles de interleuquina-6 (IL6) e interferón-α (IFN-α) en el líquido crevicular gingival de pacientes VIH-1-positivos y VIH-1-negativos con periodontitis crónica y diferentes grados de destrucción e inflamación tisular. Se obtuvieron muestras del surco crevicular gingival de 35 individuos VIH-1 positivos con periodontitis crónica y 35 pacientes seronegativos con periodontitis crónica. Se evaluaron la profundidad de sondeo y el nivel de inserción clínica, así como los resultados del Ensayo Inmunoabsorbente Ligado a Enzimas para la confirmación del diagnóstico del paciente. Los análisis estadísticos se realizaron utilizando pruebas t de Student, Mann-Whitney y Spearman. Los niveles de IL-6 fueron significativamente más bajos, mientras que los niveles de IFN-a fueron significativamente más altos en los pacientes con VIH-1. El nivel de inserción clínica se asoció directamente con los niveles de IFN-α en los portadores del VIH1, conectados a la profundidad del sondaje en estos pacientes. Los datos clínicos en asociación con los niveles de citoquinas de los fluidos creviculares gingivales pueden revelar un patrón de respuesta inmunológica localizado, que puede contribuir a la comprensión de la patogénesis de la periodontitis en los portadores del VIH-1.

Non-polarized cytokine profile of a long-term non-progressor HIV infected patient

ABSTRACT The HIV-1 initial viral infection may present diverse clinical and laboratory course and lead to rapid, intermediate, or long-term progression. Among the group of non-progressors, the elite controllers are those who control the infection most effectively, in the absence of antiretroviral therapy (ART). In this paper, the TH1, TH2 and TH17 cytokines profiles are described, as well as clinical and laboratory aspects of an HIV-infected patient with undetectable viral load without antiretroviral therapy. Production of IL-6, IL-10, TNF-α, IFN-γ, and IL-17 was detected; in contrast IL-4 was identified. Host-related factors could help explain such a level of infection control, namely the differentiated modulation of the cellular immune response and a non-polarized cytokine response of the TH1 and TH2 profiles.

Assessing endocrine and immune parameters in human immunodeficiency virus-infected patients before and after the immune reconstitution inflammatory syndrome

ABSTRACT Objective The present study compares immune and endocrine parameters between HIV-infected patients who underwent the Immune Reconstitution Inflammatory Syndrome (IRIS-P) during antiretroviral therapy (ART) and HIV-patients who did not undergo the syndrome (non-IRIS-P). Materials and methods Blood samples were obtained from 31 HIV-infected patients (15 IRIS-P and 16 non-IRIS-P) before ART (BT) and 48 ± 2 weeks after treatment initiation (AT). Plasma Interleukin-6 (IL-6) and Interleukin-18 (IL-18) were determined by ELISA. Cortisol, dehydroepiandrosterone sulfate (DHEA-S) and thyroxin concentrations were measured using chemiluminescence immune methods. Results Concentrations of IL-6 (7.9 ± 1.9 pg/mL) and IL-18 (951.5 ± 233.0 pg/mL) were significantly higher (p < 0.05) in IRIS-P than in non-IRIS-P (3.9 ± 1.0 pg/mL and 461.0 ± 84.4 pg/mL, respectively) BT. Mean T4 plasma level significantly decreased in both groups of patients after treatment (p < 0.05). In both groups cortisol levels were similar before and after ART (p > 0.05). Levels of DHEA-S in IRIS-P decreased AT (1080.5 ± 124.2 vs. 782.5 ± 123.8 ng/mL, p < 0.05) and they were significantly lower than in non-IRIS-P (782.5 ± 123.8 vs. 1203.7 ± 144.0 ng/mL, p < 0.05). IRIS-P showed higher values of IL-6 and IL-18 BT and lower levels of DHEA-S AT than in non-IRIS-P. Conclusion These parameters could contribute to differentiate IRIS-P from non-IRIS-P. The significant decrease in DHEA-S levels in IRIS-P after ART might suggest a different adrenal response in these patients, which may reflect the severity of the disease.

Social conditions and immune response in human immunodeficiency virus-seropositive pregnant women: a cross-sectional study in Brazil

Abstract INTRODUCTION The functioning of the immune system during pregnancy is altered in both human immunodeficiency virus (HIV)-infected and uninfected women. Unfavorable socioeconomic conditions have been indicative of higher morbidity and mortality and worsening of the immune system. The aim of this study was to correlate social status with levels of interleukin (IL)-10 (non-inflammatory) and interferon-gamma (IFN-γ; inflammatory) cytokines. METHODS A cross-sectional study was conducted with three groups of women: 33 pregnant HIV-infected (G1); 40 non-pregnant, HIV-infected (G2); and 35 pregnant, HIV-uninfected. To measure the social status, a compound indicator called the social status index (SSI), was established using sociodemographic variables (i.e., education level, housing conditions, per capita income, and habitation and sanitary conditions). RESULTS The HIV-infected women had a higher proportion of unfavorable SSI (73% and 75% of G1 and G2, respectively). There were significantly lower IL-10 levels in the G1 group with both unfavorable and favorable SSI than in the other groups. No significant difference in IFN-γ levels was observed among groups. However, the G1 group had higher IFN-γ values among both favorable and unfavorable SSI groups. CONCLUSIONS Higher rates of unfavorable conditions, including lower education levels, IL-10 levels, and a trend for higher IFN-γ levels, were identified among HIV-infected women, pregnant and non-pregnant. These factors may interfere in health care and lead to poor outcomes during pregnancy. Therefore, we suggest that health policies could be created to specifically address these factors in this population.

Condición inmunológica y virológica de los pacientes adultos con infección por VIH al inicio de la terapia anti-retroviral en el Hospital Carlos van Buren. Comparación de los períodos 2013 y 2015 / Immunological and virological condition of adult patients with HIV infection at the beginning of antiretroviral therapy at Carlos van Buren Hospital. Comparison of 2013 and 2015 periods

Resumen Introducción: La terapia anti-retroviral (TARV) en pacientes con infección por VIH ha causado una disminución de la morbimortalidad y del riesgo de transmisión. Las recomendaciones internacionales actuales sugieren un inicio precoz de TARV, independiente del recuento de linfocitos T CD4. Objetivo: Describir el impacto del inicio de TARV en el recuento de CD4 y carga viral (CV) al año de tratamiento en pacientes que ingresaron al Programa de VIH del HCVB en los años 2013 y 2015. Métodos: Estudio descriptivo que incluyó a todos los pacientes que iniciaron TARV durante los años mencionados. Resultados: 78 y 100 pacientes iniciaron TARV el año 2013 y 2015; respectivamente. El año 2013, 48 (61,5%) pacientes, y el año 2015, 55 (55%) pacientes iniciaron terapia con un recuento de CD4 > 200 céls/mm3. En el primer grupo, al año de seguimiento, 43 (55%) pacientes tuvieron una CV indetectable; mientras que en el segundo grupo, esta meta se logró en 72% de los casos (p = 0,001). Conclusiones: El inicio temprano de TARV aumentó la proporción de pacientes con CV indetectable. Sin embargo, debemos mejorar las estrategias para optimizar los resultados.

Introduction: Anti-retroviral therapy (ART) in HIV patients has shown reduction in morbidity and mortality, and decrease in contagious risk. International recommendations include early initiation of ART, irrespectively of CD4 cell count. Objective: To describe the impact of ART initiation in CD4 cell count and viral load at the end of the first year of HIV treatment, for patients who entered the program at 2013 and 2015. Methodology: Descriptive study. The sample comprehends all patients who started their ART treatment in the indicated years, at HCVB. Results: 78 and 100 patients initiated ART treatment in 2013 and 2015, respectively. In 2013, 48 out of 78 patients (61.5%), and in 2015, 55 (55%) patients started therapy with CD4 > 200 cell/mm3. The follow-up in the first group resulted on 43 (55%) patients with an undetectable CV at the end of first year of treatment, meanwhile in the second group 72% achieved this target (p = 0.001). Conclusions: Early ART initiation increased the proportion of patients with undetectable CV. However, we must improve strategies to optimize results.